Maternal and neonatal outcomes of vitamin D supplementation in hypovitaminosis D pregnancy: preg-D randomized trial
Authors' conclusion
Higher dose vitamin D supplementation safely achieved biochemical sufficiency in mothers and neonates without measurable effect on neonatal bone outcomes.
Study context
- Population
- Pregnant women ≤17.5 weeks' gestation with baseline 25(OH)D 10 to 30 ng/mL192 pairs analysed
- Comparison
- Vitamin D3 20 000 IU/week vs 10 000 IU every 2 weeks
- Primary endpoint
- Proportion of women achieving 25(OH)D ≥20 ng/mL at delivery and neonatal BMC at ∼1 month of age
Methodological detailsdouble-blind, 25(OH)D by LC-MS/MS at a CDC-certified laboratory
- Double-blind
- 25(OH)D by LC-MS/MS at a CDC-certified laboratory
Primary result
As reported in the abstract
25(OH)D ≥20 ng/mL at delivery
25(OH)D ≥20 ng/mL at delivery
Neonates
- Higher dose vs Lower dose: P = 0.001
Further findings
| Outcome | P value |
|---|---|
| Mean 25(OH)D in mothers and neonates · delivery | P = 0.001 |
- Neonatal subtotal whole-body bone mineral content (BMC) · ∼1 month of age — Neonatal subtotal whole-body BMC did not differ between groups (mean ± SD, higher vs lower dose)
- 45.9 ± 8.5 vs 42.2 ± 7.1 g · P = 0.059
- Neonatal subtotal whole-body BMC: 67 neonates had evaluable DXA scans
Mean 25(OH)D in mothers and neonates · delivery
- Mean 25(OH)D in mothers and neonates at delivery followed a similar pattern
Neonatal subtotal whole-body BMC · ∼1 month of age
- Neonatal BMD and bone area did not differ between groups
Safety
- No safety concerns related to supplementation identified
Original publication
Maternal and neonatal outcomes of vitamin D supplementation in hypovitaminosis D pregnancy: preg-D randomized trial. J Clin Endocrinol Metab. Published 16 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →